Secondary Sclerosing Cholangitis in Critically Ill Patients: Clinical Presentation, Cholangiographic Features, Natural History, and Outcome

A Series of 16 Cases

Silke Leonhardt, MD, Wilfried Veltzke-Schlücker, MD, Andreas Adler, MD, Eckart Schott, MD, PhD, Dennis Eyrich, MD, Wladimir Faber, MD, Peter Neuhaus, MD, PhD, and Daniel Seehofer, MD, PhD

Abstract: Secondary sclerosing cholangitis in critically ill patients (SSC-CIP) is an important differential diagnosis in patients presenting with cholestasis and PSC-like cholangiographic changes in endoscopic retrograde cholangiography (ERC). As a relatively newly described entity, SSC-CIP is still underdiagnosed, and the diagnosis is often delayed. The present study aims to improve the early detection of SSC-CIP and the identification of its complications.

A total of 2633 records of patients who underwent or were listed for orthotopic liver transplantation at the University Hospital Charité, Berlin, were analyzed retrospectively. The clinical presentation and outcome (mean follow-up 62.7 months) of the 16 identified SSC-CIP cases were reviewed.

Cholestasis was the first sign of SSC-CIP. GGT was the predominant enzyme of cholestasis. Hypercholesterolemia occurred in at least 75% of the patients. SSC-CIP provoked a profound weight loss (mean 18 kg) in 94% of our patients. SSC-CIP was diagnosed by ERC in all patients. The 3 different cholangiographic features detected correspond roughly to the following stages: (I) evidence of biliary casts, (II) progressive destruction of intrahepatic bile ducts, and (III) picture of pruned tree. Biliary cast formation is a hallmark of SSC-CIP and was seen in 87% of our cases. In 75% of the patients, the clinical course was complicated by cholangiosepsis, cholangitic liver abscesses, acalculous cholecystitis, or gallbladder perforation. SSC-CIP was associated with worse prognosis; transplant-free survival was ~40 months (mean).

Because of its high rate of serious complications and unfavorable prognosis, it is imperative to diagnose SSC-CIP early and to differentiate SSC-CIP from other types of sclerosing cholangitis. Specific characteristics enable identification of SSC-CIP. Early cooperation with a transplant center and special attention to biliary complications are required after diagnosis of SSC-CIP.

INTRODUCTION

The diversity of sclerosing cholangiopathies seems greater than believed 30 years ago. The differential diagnosis includes, for example, IgG4-related sclerosing cholangitis, AIDS-related cholangiopathy, ischemic cholangiopathy, eosinophilic cholangitis, and primary sclerosing cholangitis (PSC). In recent years, there have been increasing numbers of reports on a new entity of sclerosing cholangiopathy. This type of secondary sclerosing cholangitis occurs in association with intensive-care treatment of patients with major surgery, trauma, burns, and other life-threatening events. Secondary sclerosing cholangitis in critically ill patients (SSC-CIP) is most likely caused by severe arterial hypotension/shock.1–3 SSC-CIP is a progressive cholestatic liver disease characterized by necrosis of the bile duct epithelium, which leads to the rapid destruction of the visible intrahepatic bile ducts. The disease runs a chronic, irreversible course and can only be cured by liver transplantation. Here, we report our experience with 16 SSC-CIP cases. The aim of our study was to define the characteristic clinical features of SSC-CIP.

MATERIALS AND METHODS

Here, we present clinical data on critically ill patients who developed secondary sclerosing cholangitis. All cases were
TABLE 1. Demographic Characteristics and Outcome of 16 Cases With SSC-CIP

| Initial life-threatening event | n  |
|-------------------------------|----|
| Polytrauma                    | 7  |
| Burn injury                   | 1  |
| Cardiac surgery               | 4  |
| Severe postoperative bleeding after gynaecologic surgery | 1 |
| Subarachnoid haemorrhage      | 1  |
| Respiratory insufficiency due to acute exacerbation of COPD | 2  |
| Total number of cases         | 16 |
| Gender (male/female)          | 11/5 |
| Male: female                  | 2.2 |
| Mean age at diagnosis (years ± SDM) | 45.87 ± 14.64 |
| Median age at diagnosis (years, range) | 48 (18–63) |
| Mean follow-up (months ± SDM) | 62.7 ± 32 |
| Median follow-up (months, range) | 62 (5.6–171) |

Duration of intensive care treatment

| Mean (days ± SDM) | 38.75 ± 23.87 |
| Median (days, range) | 31 (9–82) |

Outcome; survival free of LTx and survival after LTx

| Mean time interval—onset of cholestasis to listing for LTx (days ± SDM) | 322 ± 257 |
| Mean time interval—onset of cholestasis to listing for LTx (days, range) | 225 (78–1004) |
| Mean time interval—onset of cholestasis to LTx (days ± SDM) | 1075 ± 545 |
| Median time interval—onset of cholestasis to LTx (days, range) | 1271 (189–1718) |
| Mean survival free of LTx (days) | 1223 ± 741 |
| Median survival free of LTx (days) | 1336 (189–2472) |
| Mean survival after LTx (days) | 1187 ± 1051 |
| Median survival after LTx (days, range) | 1075 (14–2658) |

COPD = chronic obstructive pulmonary disease, LTx = liver transplantation, SDM = standard deviation of the mean, SSC-CIP = secondary sclerosing cholangitis in critically ill patients.

recruited retrospectively by reviewing the hospital records of patients who received (2473) or were listed for orthotopic liver transplantation (OLT) at the Charité University Hospital Berlin between January 1990 and May 18, 2011. Sixteen patients with a confirmed diagnosis of SSC-CIP were identified. The Charité Department of Transplantation Surgery is a tertiary care center and most cases with SSC-CIP were referred from other hospitals. Therefore, in most patients, the initial treatment—especially intensive care treatment—was performed in outside hospitals. After listing for OLT, endoscopic management of the patients was performed at the Endoscopy Unit of Department of Gastroenterology and Hepatology/Charité, a high-volume center for biliary endoscopy. All patients had survived a prior acute life-threatening event followed by intensive care treatment. The reasons for admission to the intensive care unit (ICU) are shown in Table 1. Before admission to ICU, no patient had evidence of liver or bile duct disease and had unremarkable liver function tests. Clinical information about each patient was obtained by review of the medical records. Detailed pieces of information regarding the clinical course, laboratory parameters, ultrasound and endoscopic retrograde cholangiography (ERC) findings were collected. The diagnosis of SSC-CIP was established by ERC (16/16) and confirmed by liver histology (12/16 patients). The median follow-up was 62 months (range: 5.6–171). The onset of cholestasis was defined as an increase in the cholestatic parameters (gamma-glutamyltransferase [GGT], alkaline phosphatase [ALP], and bilirubin) to more than twice the upper limit of normal. Data were summarized as mean and standard deviation of the mean or were presented as medians with ranges or percentages. We tested for gender differences using the 2-sided binomial probability test. Cholesterol elevation was tested for significance with the 2-sided 1-sample t test. P values of <0.05 were regarded as statistically significant. Statistical analyses were performed using Stata software, version 13.1 (Stata Corp). Transplant-free survival curves were calculated by the Kaplan–Meier method. The starting point for survival analysis was defined as the time of onset of cholestasis. Either liver transplantation or death from liver disease was counted as an event, whereas “patients alive without liver transplantation” was censored. The study was approved by the local Ethics Committee of the Charité, and all surviving patients gave their written informed consent to having their data recorded.

RESULTS

At time of diagnosis, the patients had a mean age of 46 ± 14.6 years. All patients required intensive care treatment for a mean 39 ± 23.9 days (Table 1). The disease showed a tendency to affect men more often than women (11 men to 5 women, ratio of 2.2), but the difference was not significant (P = 0.210, 2-sided binominal probability test).

Liver Function Tests and Other Laboratory Parameters

The onset of cholestasis was seen 7 days (median) after the initial life-threatening event. Gamma-glutamyl-transferase
Cholestasis reached a peak after 31 days (range: 14–68 days). GGT levels peaked at 281.9 U/L for AST, and 271.4 U/L for ALT). Hyperbilirubinemia could be observed after a mean of 15.5 ± 10 days (median: 13 days) and was therefore the last sign of disease detected. This characteristic sequence of GGT, ALP, and bilirubin elevation was observed in 13/16 patients (Fig. 1). Diagnostic Studies

Ultrasound: For differential diagnosis of the cholestasis, ultrasound scans were performed in all 16 patients, starting 10.5 days (mean: 29.31 ± 60.05 days; range 1–247 days) after the onset of cholestasis. Dilatation of the extrahepatic bile duct was observed in 31% (5/16) of the patients. Isolated intrahepatic cholestasis was detected in another 2 patients, bringing the total number of cases with biliary system abnormalities to 7/16. Furthermore, sonographic signs of cholecystitis were observed in 8/16 patients. A total of 88% of the patients developed sonographic signs of liver cirrhosis within 6 months (mean).

Liver histology: Liver histology data were available in 11/16 cases, either by liver biopsy, autopsy, or by histological findings from the explanted liver. The liver biopsy specimens were obtained 22 to 351 days after the onset of cholestasis (mean: 133 ± 124 days; median: 102 days). All biopsy specimens showed histopathological changes, which were located mainly in the portal tracts. Abnormalities such as portal tract dilatation, ductular reaction, and portal tract infiltration were described. Fibrosis of portal tracts was detected in 5 of 6 liver biopsies. Cirrhosis was found in 7/9 of the explanted livers and portal fibrosis was detected in 2/9 patients with early transplantation on day 189 and 237 (Table 2). In the explanted livers, the histological evidence of necrosis of the larger bile ducts in the hilar region is particularly worth mentioning (Supplement 1, http://links.lww.com/MD/A550).

Weight Loss

Severe weight loss (mean: 18 ± 11 kg; median: 18.5 kg) occurred in the first year after the initial injury in 15/16 patients. The amount of weight loss was not associated with the length of the early stage of disease was characterized by the presence of multiple ribbon-like intraductal filling defects in the biliary tract. These filling defects were consistent with biliary casts and were found in 87% (14/16) of our patients in the first year after the initial injury. The shortest and longest time until detection was 13 and 265 days after the onset of cholestasis. In 3 patients, no signs of biliary cast formation were detected during the first ERC session but were observed later on the third or fourth ERC session. In 7/14 patients, biliary casts were found in multiple consecutive ERC sessions.

II. Intermediate Stage: Progressive Destruction of the Intrahepatic Bile Ducts

The further course of the disease was characterized by rapidly progressive intrahepatic bile duct destruction beyond the second bifurcation of the intrahepatic bile ducts. The destruction of the intrahepatic bile ducts due to epithelial necrosis manifests at ERC as contour defects and irregular wall contours.

III. Late Stage: Obliteration of the Intrahepatic Bile Ducts/Picture of Pruned Tree

As a result of the progressive destruction, the intrahepatic bile duct branches were eventually obliterated, leaving only a rudimentary central biliary system (see also Fig. 3). In ERC, contrast enhancement of the bile ducts occurred only below the second bifurcation. In the later stage, the picture was that of a pruned tree. At least one side of the biliary system was obliterated, but mostly both sides were affected. The median time to the appearance of this constellation was 86.5 days after the onset of cholestasis (mean: 133 ± 127 days).

Liver histology: Liver histology data were available in 11/16 cases, either by liver biopsy, autopsy, or by histological findings from the explanted liver. The liver biopsy specimens were obtained 22 to 351 days after the onset of cholestasis (mean: 133 ± 124 days; median: 102 days). All biopsy specimens showed histopathological changes, which were located mainly in the portal tracts. Abnormalities such as portal tract dilatation, ductular reaction, and portal tract infiltration were described. Fibrosis of portal tracts was detected in 5 of 6 liver biopsies. Cirrhosis was found in 7/9 of the explanted livers and portal fibrosis was detected in 2/9 patients with early transplantation on day 189 and 237 (Table 2). In the explanted livers, the histological evidence of necrosis of the larger bile ducts in the hilar region is particularly worth mentioning (Supplement 1, http://links.lww.com/MD/A550).

Weight Loss

Severe weight loss (mean: 18 ± 11 kg; median: 18.5 kg) occurred in the first year after the initial injury in 15/16 patients. The amount of weight loss was not associated with the length of the disease.
### TABLE 2. Laboratory and Clinical Characteristics of 16 Cases With SSC-CIP

| No. | Sex | Age (yrs) | Duration of ICU Treatment (d) | Peak Level of GGT/C2 Times the Upper Limit of Normal | Peak Level of ALP/C2 Times the Upper Limit of Normal | Peak Level of Bilirubin/C2 Times the Upper Limit of Normal | Weight Loss (kg) | BMI at Time of Initial Event | BMI During Course of SSC-CIP | Cholesterol Before LTx/C3 (mg/dL) | Cholesterol After LTx/C0 (mg/dL) | Creatinine (mg/dL) | Pruritus | Sonographic Signs of LC/L ¼ liver signs S ¼ splenomegaly | Histology |
|-----|-----|-----------|-----------------------------|-----------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------|-----------------|---------------------------|-------------------------------|-----------------------------------|---------------------------------|------------------|---------|------------------------------------------------|----------|
| 1   | F   | 63       | 28                          | 40                                                  | 52× 16                                              | 15× 39                                                  | 17              | 26.7                      | 19.70                          | n.a.                              | 144                             | <1.3              | n.a.    | n.a.                                      | E:ppF       |
| 2   | M   | 25       | 24                          | 15                                                  | 9.4× n.a.                                           | n.a.                                                     | 13              | 22.9                      | 18.5                           | 314                               | E:ppF                                           | <1.3              | n.a.    | –                       | S/11mo B: ppF |
| 3   | M   | 43       | 23                          | 36                                                  | 21× n.a.                                            | 11× n.a.                                                 | 20              | 27.1                      | 20.3                           | 4.4× 13                            | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/24 mo E:ppF |
| 4   | M   | 49       | 70                          | 40                                                  | 10× 32                                              | 8× 122                                                | 467             | 121                       | 24.6                           | 14× 122                            | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 5   | M   | 49       | 70                          | 40                                                  | 10× 32                                              | 8× 122                                                | 467             | 121                       | 24.6                           | 14× 122                            | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 6   | M   | 33       | 48                          | 26                                                  | 17× 13                                              | 8× 122                                                | 238             | 102                       | 15.5                           | 2× 122                            | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 7   | M   | 53       | 15                          | 14                                                  | 7× 3.1                                              | 50× 32                                                | 32               | 17.5                      | 238                           | 102                               | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 8   | M   | 57       | 77                          | 25                                                  | 8× 23.5                                             | 5× 20                                                 | 20               | 13.9                      | 12.4                           | 3× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 9   | M   | 18       | 82                          | 21                                                  | 5× 6.8                                              | 5× 36                                                 | 26              | 10.4                      | 18.4                           | 3× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 10  | M   | 34       | 13                          | 36                                                  | 13× 7× 7.5                                          | 5× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 11  | M   | 47       | 39                          | 13                                                  | 3× 3.7                                              | 3× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 12  | F   | 47       | 39                          | 13                                                  | 3× 3.7                                              | 3× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 13  | M   | 47       | 39                          | 13                                                  | 3× 3.7                                              | 3× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 14  | F   | 57       | 17                          | 13                                                  | 3× 3.7                                              | 3× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 15  | M   | 57       | 17                          | 13                                                  | 3× 3.7                                              | 3× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |
| 16  | F   | 34       | 13                          | 36                                                  | 13× 7× 7.5                                          | 5× 22.8                                                | 28              | 16.5                      | 15.8                           | 2× 20                              | E:ppF                                           | <1.3              | n.a.    | n.a.                                      | B/6 mo E:ppF |

### Notes
- **A** ¼ autopsy, **ALP** ¼ alkaline phosphatase (women 55–147 IU/L; men 62–176 IU/L), **B** ¼ biopsy, **bilirubin** ¼ total bilirubin (upper limit of normal ¼ 1.2 mg/dL), **BMI** ¼ body mass index, kg/m², **cholesterol** ¼ upper limit of normal ¼ 200 mg/dL, **creatinine** ¼ upper limit of normal ¼ 1.3 mg/dL, **E** ¼ liver explants, **GGT** ¼ gamma-glutamyltranspeptidase (women <36 IU/L; men <61 IU/L), **ICU** ¼ intensive care unit, **LC** ¼ liver cirrhosis, **LTX** ¼ liver transplantation, n.a. ¼ data not available, pp. ¼ primary punctum after the initial event, times the upper limit of normal.
- Within the 1st year after the initial event.
ICU stay and occurred, in some cases, despite a short period of intensive care treatment (Table 2).

Complications of SSC-CIP

Biliary complications occurred in 87.5% of our patients. Recurrent cholangitic episodes/flare-ups were documented in 12/14 patients (no data were available for the remaining 2 patients). In 3/16 patients liver abscess formation was observed. Severe cholangiosepsis was seen in 3/16 (19%) patients (Table 3, Fig. 4).

Involvement of the gallbladder: Immediately following cholestasis onset, one-half of our patients had sonographic signs of acute (predominantly acalculous) cholecystitis. Within the 1st year after initial injury acute cholecystitis occurred in 69% (11/16) of the patients. Of these, 45% (5/11) required emergency cholecystectomy. The cholecystitis described was mostly an acalculous cholecystitis (10/11). Gallbladder perforation evolved in 2 of these patients—in 1 patient 24 days after the onset of cholestasis. The perforation rate was thus 18% (2/11).

Outcome, Progression, Listing, Need for Transplantation

The data relating to outcome and transplantation are shown in Tables 1 and 3 and Figure 5. After a short course of disease, clinical signs and symptoms of liver cirrhosis appeared within a few months. Most of the patients in our series (12/16) had to be placed on the waiting list for liver transplant within 1 year after the onset of cholestasis. The mean time to listing was 322 ± 257 days (median: 225 days). The mean time from the onset of cholestasis until transplantation was 35 months (median: 42 months). The earliest transplantation was performed 189 days after the onset of cholestasis in a 63-year-old woman who developed cholangiosepsis and multiple organ failure.
DISCUSSION

If ERC demonstrates PSC-like cholangiographic findings, all types of sclerosing cholangiopathy must be considered in the differential diagnosis. This includes secondary sclerosing cholangitis in critically ill patients (SSC-CIP). With mortality rates of up to 50%, SSC-CIP represents a challenge to gastroenterologists and intensive care specialists. Currently, SSC-CIP is still widely underdiagnosed. Early detection of the disease and its complications is crucial to improving the poor prognosis.

In the initial stages of the disease, SSC-CIP must be recognized as a cause of liver failure in ICU patients. In the later stages, SSC-CIP must be differentiated from other types of sclerosing cholangiopathy. This differentiation is necessary with regard to the selection and timing of liver transplantation as SSC-CIP progresses much more rapidly than other cholangiopathies. To enable clinical differentiation, characteristic features of SSC-CIP must be identified.

As its name indicates critical illness is an obligatory precondition for SSC-CIP.1–5 All of our patients had a history of intensive care treatment for a life-threatening event. Although this event often necessitates lengthy intensive care treatment, long-term treatment (>7 days) is not required for the destruction of the bile ducts, as previously believed. Rather, it seems that bile duct damage is a very early event that manifests within the first 5 to 7 days, as evidenced by the early increase of cholestatic enzymes in our series.

There is a trend that the disease affects men more often than women. In addition, SSC-CIP showed a predilection for surgical patients, especially those in whom extensive tissue destruction occurs, such as patients with polytrauma or those undergoing major surgery. The first detectable sign of SSC-CIP was an increase in the liver enzymes—as our data confirm. SSC-CIP was characterized by a cholestatic pattern. In our patients, GGT was the predominant enzyme, which increased earlier and peaked more markedly than ALP. Hyperbilirubinemia occurred in the later stages. Although not specific, these laboratory findings may be helpful in distinguishing SSC-CIP from other causes of elevated liver enzymes in ICU patients, for example, from sepsicaemia-associated cholestasis, in which a hyperbilirubinemia predominates.6–8

Our data show that SSC-CIP is associated with markedly elevated serum cholesterol. Elevated levels of cholesterol are common in primary biliary cirrhosis (PBC), but occur less frequently in PSC.9–10 In SSC-CIP, the combination of elevated serum-cholesterol and pruritus may reflect disturbed bile acid metabolism.

Unintentional weight loss appears to be a typical feature of SSC-CIP and affected 94% of our patients. This contrasts with reports of weight loss in only 35% to 40% of PSC patients.11 Losing a mean 18 kg, our patients experienced a reduction of total fat mass.12

Diagnosis

Cholangiography is mandatory for the diagnosis of SSC-CIP. In clinical practice, the decision to perform endoscopic retrograde cholangiography (ERC) in ICU patients with cholestasis is often based on ultrasound findings of dilated bile ducts. However, this approach delayed the diagnosis in our series since only a few patients had dilated extrahepatic bile ducts. Therefore, despite of the severe and striking initial course of SSC-CIP, it took 3 months (mean) to establish the final diagnosis. Typical ERC findings were biliary casts, destruction of intrahepatic bile ducts, or finally the picture of a “pruned tree.” These 3 different ERC findings occurred consecutively and might reflect distinct stages in the development of the disease. However, overlapping stages have also been observed. Our findings show that SSC-CIP is mainly a disease of the visible intrahepatic bile ducts—the extrahepatic bile ducts were only marginally affected. Biliary cast formation may be considered pathognomonic for SSC-CIP, as suggested by the high proportion of patients with biliary casts in our series. The casts completely fill the bile ducts and may distend them. In all patients initially presenting sonographically distended extrahepatic bile ducts, the first ERC’s revealed biliary casts. The occurrence of biliary casts in association with either PSC or IgG4 cholangiopathy has not been described in the literature.

After liver transplantation, the occurrence of biliary casts is a known phenomenon, and an etiological association with ischemic events is assumed.13,14 However, single cases of “biliary cast syndrome” in nontransplant patients have also been described.15–18 This “biliary cast syndrome” in nontransplant patients is presumably not a separate entity, but rather an early stage of SSC-CIP, as supported by some case reports.19,20 In agreement with data from orthotopic liver transplantation we found biliary casts in SSC-CIP only within the first year after the initial event.13 Despite successful initial endoscopic removal, 7 of our patients showed recurrence of the biliary casts at subsequent ERC examinations. Whether these were merely the result of a sliding down of incompletely removed intrahepatic fragments, or whether new casts were formed is not clear.

Complications of SSC-CIP

SSC-CIP carries a high risk for hepatobiliary complications. In 75% of our patients the clinical course was complicated by acute acalculous cholecystitis, gallbladder perforation, cholangitic liver abscess, or cholangiosepsis.

Involvement of the Gallbladder

It seems that the gallbladder epithelium is involved in the pathogenetic process in SSC-CIP. This is underscored by the high rate of acute cholecystitis (in the absence of a cholelithiasis) in the early stage of disease in our series. Acute acalculous cholecystitis (AAC) is a serious and potentially fatal condition. Ischemic necrosis of the gallbladder wall, often extending into the deeper layers, causes a high spontaneous perforation rate, as our data confirm. It is known that acute acalculous cholecystitis shows a predilection to occur in critically ill patients after trauma, burns, or major surgery.21–23 Because acute acalculous cholecystitis has also been observed in association with Schönlein–Henoch purpura, antiphospholipid syndrome and lupus erythematosus, an ischemic pathogenesis for AAC is supposed.24–26 A similar pathogenetic mechanism that could explain the gallbladder involvement is hypothesized for SSC-CIP. In ICU patients, an unexplained cholestasis and the simultaneous appearance of acute acalculous cholecystitis should raise the suspicion of SSC-CIP. Conversely, acute acalculous cholecystitis is not a known phenomenon in patients with PSC or IgG4-associated cholangiopathy.
| No. | Sex | Age (yrs) | Follow-Up (Months) | Initial Event | Cholangitic Episodes | Cholangiosepsis | Liver Abscess | Cholecystitis | G B P | CCE | Time Cholestasis to LTx (d) | Survival Free of LTx (d) |
|-----|-----|-----------|--------------------|---------------|---------------------|----------------|--------------|--------------|--------|-----|------------------------------|--------------------------|
| 1   | F   | 63        | 90                | Severe postoperative bleeding after gynecologic surgery | +       | +       | +       | +       | –   | –   | 189                         | 189                       |
| 2   | M   | 25        | 81.6              | Polytrauma     | +       | –       | –       | –       | –   | –   | w. l.                         | 2472                      |
| 3   | M   | 43        | 77                | Polytrauma     | +       | –       | –       | + (H)    | +   | +   | w. l.                         | 2337                      |
| 4   | M   | 26        | 70.8              | Polytrauma     | n.a.    | –       | +       | –       | +   | –   | w. l.                         | 2143                      |
| 5   | M   | 49        | 124               | Polytrauma     | +       | –       | –       | +       | –   | +   | 961                          | 961                       |
| 6   | M   | 33        | 69                | Polytrauma     | +       | –       | –       | +       | –   | –   | 1718                         | 1718                      |
| 7   | M   | 53        | 46.8              | Subarachnoid hemorrhage | –       | –       | –       | + (CL)   | +   | –   | w. l.                         | 1402                      |
| 8   | M   | 57        | 33.8              | Heart transplantation | +       | –       | –       | +       | +   | +   | w. l.                         | 1022                      |
| 9   | M   | 18        | 10.3*             | Burn injury    | +       | +       | –       | –       | –   | –   | 315 death                    |                           |
| 10  | F   | 46        | 56                | Respiratory insufficiency/pneumonia/acute exacerbation of COPD | n.a.    | –       | –       | –       | –   | –   | 1465                         | 1465                      |
| 11  | F   | 60        | 56                | Heart transplantation | +       | –       | –       | +       | –   | –   | 237                          | 237                       |
| 12  | M   | 63        | 67.5              | Polytrauma     | +       | –       | –       | –       | –   | –   | 967                          | 967                       |
| 13  | F   | 47        | 49.7*             | Respiratory insufficiency/acute exacerbation of COPD | +       | –       | –       | +       | –   | –   | 1271                         | 1271                      |
| 14  | M   | 57        | 5.6               | Aortic-dissection+ surgery for aortic dissection | –       | –       | –       | –       | –   | –   | w. l.                         | 166                       |
| 15  | M   | 34        | 117.5             | Polytrauma     | +       | –       | –       | + (H)    | –   | –   | 1467                         | 1467                      |
| 16  | F   | 60        | 47.3*             | Emergency aorto-coronary-bypass | +       | +       | –       | +       | –   | –   | 1434 death                   |                           |

CCE = cholecystectomy, CL = cholecystolithiasis, COPD = chronic obstructive pulmonary disease, GBP = gall bladder perforation, H = gallbladder hydrops, LTx = Liver transplantation, n.a = data not available, SSC-CIP = secondary sclerosing cholangitis in critically ill patients.

*dead.
Cholangitic Episodes/Cholangiosepsis/Liver Abscesses

In our patients, the clinical course of disease was complicated by recurrent episodes of bacterial cholangitis. In SSC-CIP, these episodes may be secondary events explainable by the presence of multifocal intrahepatic biliary strictures due to extensive destruction of segmental and subsegmental bile ducts. Furthermore, as a result of the duct damage peripheral bile duct branches can lose their connection to the central ducts and become “excluded” bile ducts. The elimination of a biliary obstruction is a prerequisite for successful antibiotic treatment of cholangitis. Unfortunately in SSC-CIP this drainage is frequently inadequate since peripheral, “excluded” ducts often can no longer be reconnected by endoscopic means. The remaining obstruction impairs the penetration of antibiotics into bile, limits the effectiveness of the treatment, and increases the risk of cholangiosepsis. In the absence of drainage the mortality rate of cholangitis is high, as known from the pre-ERC era.27–30 This problem is reflected by our data, showing a high rate of cholangiosepsis, and among these patients a high fatality rate. Two of 3 patients died from cholangiosepsis while still on the transplant waiting list. Furthermore, the stagnation of bile flow also promotes cholangitic liver abscesses—almost 19% of our patients developed this complication.

Progression/Need for Transplantation

Two aspects contributed to the short latency between the onset of cholestasis and the need for transplantation observed in our SSC-CIP cases. First, the clinical and histology data indicate that the liver fibrosis progressed unusually quickly over a period of a couple of months. This rapid and extensive fibrotic response may be explainable by the large extent of initial cholangiocyte destruction of the intrahepatic bile ducts.31 Second, on account of the risk of cholangiosepsis, transplantation is urgently needed in cases with irreversible destruction of bile ducts and recurrent severe cholangitis. Two patients of our series died of cholangiosepsis while still on the transplant waiting list; another patient with cholangiosepsis and multiple organ failure had to be transplanted 195 days after the initial event. Median liver transplantation-free survival was only 44 months (mean 40 months) in our patients, compared to 89 to 112 months in other fibrosing cholangiopathies such as PSC, and 72 months in “classical” infective SSC.32–34 In view of the more rapid disease progression, patients with SSC-CIP require closer monitoring than patients with other forms of fibrosing cholangiopathy and an early cooperation with a transplantation center should be initiated.35,36

Survival After Liver Transplantation

It was assumed earlier that patients with secondary sclerosing cholangitis had a poor outcome after liver transplantation.33,37 Our findings refute this. Eight of the 9 transplanted patients are alive and in a good state of health. Only 1 female patient, who underwent simultaneous liver and lung transplantation, died from pulmonary complications. The resulting 1-year survival rate of 85% and 3-year survival rate of 83% correspond well with the survival rates for OLT in alcoholic liver cirrhosis.

Study Limitations

The limitations of the present study are its retrospective nature and the recruitment of the patients from a transplantation center. Patients with an initially severe course who did not live long enough to be listed, as also those with a milder course and no liver transplantation, were not included in the study. Further larger clinical studies can build on and consolidate our results. Prospective studies with a control group, which makes it possible to perform complex statistics generating \( P \) values would be needed to validate our observations.

Frequency of SSC-CIP

The actual prevalence of SSC-CIP remains unknown and is also not adequately reflected in our data (due to selection bias, as mentioned above). Overall, 0.61% of all liver transplantations performed at our center were due to SSC-CIP. Similar rates have been observed, for example, in patients with...
hemochromatosis (0.7% of all OLT at our center). For PSC the figure was 6.2% in our center, indicating that SSC-CIP is 10 times rarer than PSC.

**CONCLUSION**

Despite some similarities with other sclerosing cholangiopathies, SSC-CIP shows characteristic features that allow for discrimination of SSC-CIP from other entities. In particular, the occurrence of biliary casts in patients with equivocal findings of sclerosing cholangiopathy in ERC is suggestive of SSC-CIP and excludes PSC and IgG4 cholangiopathies. Last but not least, the fatal outcome of the complications of SSC-CIP could be prevented by better recognition of the disease and its natural history.

**ACKNOWLEDGMENTS**

The authors wish to thank Peter Palm, Berlin, for the graphic design in Figure 2 and H. Niggemann for statistical analysis.

**REFERENCES**

1. Schmitt M, Köhl CB, Müller MK, et al. Sclerosing cholangitis after burn injury. Z Gastroenterol. 1997;35:929–934.
2. Leonhardt S, Veltzke-Schlieker W, Adler A, et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care. Doi: 10.1186/s13054-015-0861-5 [Epub ahead of print].
3. Jaeger C, Mayer G, Henrich R, et al. Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow-up. *Endoscopy*. 2006;38:730–734.
4. Gelbmann CM, Rümmele P, Wimmer M, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. *Am J Gastroenterol*. 2007;102:1221–1229.
5. Voigtla¨nder T, Negm AA, Schneider AS, et al. Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome. *Endoscopy*. 2012;44:1055–1058.
6. Bansal V, Schuchert VD. Jaundice in the intensive care unit. *Surg Clin North Am*. 2006;86:1495–1502.
7. Kortgen A, Paxian M, Werth M, et al. Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. *Shock*. 2009;32:358–365.
8. Chand N, Sanyal AJ. Sepsis-induced cholestasis. *Hepatology*. 2007;45:230–241.
9. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. *Lancet*. 2003;362:53–61.
10. Sinakos E, Abbas G, Jorgensen RA, et al. Serum lipids in primary sclerosing cholangitis. *Dig Liver Dis*. 2012;44:44–48.
11. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. *Hepatology*. 1989;10:430–436.
12. Batista ML Jr, Peres SB, McDonald ME, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. *Cytokine*. 2012;57:9–16.
13. Shah JN, Haigh WG, Lee SP, et al. Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. *Am J Gastroenterol*. 2003;98:1861–1867.
14. Gor NV, Levy RM, Ahn J, et al. Biliary cast syndrome following liver transplantation: predictive factors and clinical outcomes. *Liver Transpl*. 2008;14:1466–1472.
15. Gleeson FC, Czaja AJ, Baron TH. Successful endoscopic management of biliary cast syndrome in nonliver transplant patients. *J Clin Gastroenterol*. 2008;42:752–755.
16. Kusnierz K, Nowakowska-Dulawa E, Pilch-Kowalczyk J, et al. Biliary cast syndrome in a non-transplant patient with acute pancreatitis. *Dig Liver Dis*. 2012;44:534–535.
17. Hosoi M, Nannya Y, Sasaki T, et al. Biliary cast syndrome and benign biliary stricture as complications of allogeneic hematopoietic stem cell transplantation. *Ann Hematol*. 2010;89:1287–1289.
18. Dziurkowska-Marek A, Hartleb M, Marek TA, et al. Fatal case of biliary cast syndrome in nontransplant patient. *Endoscopy*. 2008;41(Suppl 2):E256.
19. Byrne MF, Chong HI, O’Donovan D, et al. Idiopathic cholangiopathy in a biliary cast syndrome necessitating liver transplantation following head trauma. *Eur J Gastroenterol Hepatol*. 2003;15:415–417.
20. Kwon ON, Cho SH, Park CK, et al. Biliary cast formation with sclerosing cholangitis in critically ill patient: case report and literature review. *Korean J Radiol*. 2012;13:358–362.
21. Ullman M, Hasselgren PO, Tveit E. Posttraumatic and postoperative acute acalculous cholecystitis. *Acta Chir Scand*. 1984;150:507–509.
22. Castana O, Rempelos G, Anagiotos G, et al. Acute acalculous cholecystitis—a rare complication of burn injury. *Ann Burns Fire Disasters*. 2009;22:48–50.
23. Ahmed N. Acute acalculous cholecystitis complicating major trauma: a report of five cases. *South Med J*. 2008;101:1146–1149.
24. Hoffmann JC, Cremer P, Preiss JC, et al. Gallbladder involvement of Henoch–Schoëlein purpura mimicking acute acalculous cholecystitis. *Digestion*. 2004;70:45–48.
25. Bando H, Kobayashi S, Matsumoto T, et al. Acute acalculous cholecystitis induced by mesenteric inflammatory veno-occlusive disease (MIVOD) in systemic lupus erythematosus. *Clin Rheumatol*. 2003;22:447–449.
26. Desailloud R, Papo T, Vaneccolo S, et al. Acalculous ischemic gallbladder necrosis in the catastrophic antiphospholipid syndrome. *Arthritis Rheum*. 1998;41:1318–1320.
27. Blankenhorn BJ, Habib N, Mok D, et al. Decreased biliary excretion of piperacillin after percutaneous relief of extrahepatic obstructive jaundice. *Antimicrob Agents Chemother*. 1985;6:778–780.
28. Leung JW, Chan RC, Cheung SW, et al. The effect of obstruction on the biliary excretion of cepofeprazone and ceftazidime. *J Antimicrob Chemother*. 1999;25:399–406.
29. Welch JP, Donaldson GA. The urgency of diagnosis and surgical treatment of acute suppurative cholangitis. *Am J Surg*. 1976;131:527–532.
30. O’Connor MJ, Schwartz ML, McQuarrie DG, et al. Acute bacterial cholecystitis: an analysis of clinical manifestation. *Arch Surg*. 1982;117:437–441.
31. Lazaridis KN, Strazzaboso M, Marusso NF. The cholangiopathies: disorders of biliary epithelia. *Gastroenterology*. 2004;127:1565–1577.
32. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. *Best Pract Res Clin Gastroenterol*. 2001;15:563–575.
33. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. *Am J Gastroenterol*. 2005;100:1330–1333.
34. Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. *Gut*. 1996;38:610–615.
35. Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. *Hepatology*. 1992;16:1290–1299.
36. Farges O, Malassagne B, Sebagh M, et al. Primary sclerosing cholangitis: liver transplantation or biliary surgery. *Surgery*. 1995;117:146–155.
37. Kirchner GI, Scherer MN, Obed A, et al. Outcome of patients with ischemic-like cholangiopathy with secondary sclerosing cholangitis after liver transplantation. *Scand J Gastroenterol*. 2011;46:471–478.